Repository logo
 
Publication

Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics

dc.contributor.authorLima, Ana Rita
dc.contributor.authorPinto, Joana
dc.contributor.authorAmaro, Filipa
dc.contributor.authorBastos, Maria de Lourdes
dc.contributor.authorCarvalho, Márcia
dc.contributor.authorGuedes de Pinho, Paula
dc.date.accessioned2021-06-30T09:22:41Z
dc.date.available2021-06-30T09:22:41Z
dc.date.issued2021
dc.description.abstractProstate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its screening, serum prostate specific antigen (PSA) test has been largely performed over the past decade, despite its lack of accuracy and inability to distinguish indolent from aggressive disease. Metabolomics has been widely applied in cancer biomarker discovery due to the well-known metabolic reprogramming characteristic of cancer cells. Most of the metabolomic studies have reported alterations in urine of PCa patients due its noninvasive collection, but the analysis of prostate tissue metabolome is an ideal approach to disclose specific modifications in PCa development. This review aims to summarize and discuss the most recent findings from tissue and urine metabolomic studies applied to PCa biomarker discovery. Eighteen metabolites were found consistently altered in PCa tissue among different studies, including alanine, arginine, uracil, glutamate, fumarate, and citrate. Urine metabolomic studies also showed consistency in the dysregulation of 15 metabolites and, interestingly, alterations in the levels of valine, taurine, leucine and citrate were found in common between urine and tissue studies. These findings unveil that the impact of PCa development in human metabolome may offer a promising strategy to find novel biomarkers for PCa diagnosis.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationLima, A.R.; Pinto, J.; Amaro, F.; Bastos, M.d.L.; Carvalho, M.; Guedes de Pinho, P. Advances and Perspectives in Prostate Cancer Biomarker Discovery in the Last 5 Years through Tissue and Urine Metabolomics. Metabolites 2021, 11, 181. https://doi.org/10.3390/ metabo11030181pt_PT
dc.identifier.doi10.3390/metabo11030181pt_PT
dc.identifier.issn2218-1989
dc.identifier.urihttp://hdl.handle.net/10284/9975
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relationThis work was supported by the Applied Molecular Biosciences Unit—UCIBIO which is financed by national funds from FCT (UIDP/04378/2020 and UIDB/04378/2020), by FEDER—Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020—Operational Programme for Competitiveness and Internationalisation (POCI), and by Portuguese funds through FCT in the framework of the project POCI-01-0145-FEDER-030388—PTDC/SAU-SER/30388/2017pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectMetabolomicspt_PT
dc.subjectVolatilomicspt_PT
dc.subjectLipidomicspt_PT
dc.subjectProstate cancerpt_PT
dc.subjectBiomarkerspt_PT
dc.subjectMetabolic pathwayspt_PT
dc.titleAdvances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomicspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue3pt_PT
oaire.citation.startPage181pt_PT
oaire.citation.titleMetabolitespt_PT
oaire.citation.volume11pt_PT
person.familyNameCarvalho
person.givenNameMarcia
person.identifier2017111
person.identifier.ciencia-id8B10-171E-E63E
person.identifier.orcid0000-0001-9884-4751
person.identifier.ridD-5999-2013
person.identifier.scopus-author-id7201413997
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication3837b828-ba57-47f7-a811-cce65e4922c6
relation.isAuthorOfPublication.latestForDiscovery3837b828-ba57-47f7-a811-cce65e4922c6

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Advances and perspectives in prostate cancer biomarker discovery.pdf
Size:
1.42 MB
Format:
Adobe Portable Document Format